Companies › Synthekine
3 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Immunology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STK-009 human orthogonal IL-2 cytokine selective for hoRb-expressing CAR-T cells | IL2RA | Phase 1 | Systemic Lupus Erythematosus; CLL/SLL | Apr 2028 |
| SYNCAR-001 autologous CD19-targeted CAR-T cell with hoRb co-expression | – | Phase 1 | Systemic Lupus Erythematosus; CLL/SLL | Apr 2028 |
| STK-012 Engineered Interleukin-2 (IL-2) selective for antigen-activated T cells | IL2 | Phase 1 | Advanced Solid Tumor | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06544330 | SYNCAR-001 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Apr 2028 |
| NCT06544330 | STK-009 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Apr 2028 |
| NCT05665062 | SYNCAR-001 | Phase 1 | CLL/SLL | Oncology | Jun 2028 |
| NCT05665062 | STK-009 | Phase 1 | CLL/SLL | Oncology | Jun 2028 |
| NCT05098132 | STK-012 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.